Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 15, 2021, details the results of Phio Pharmaceuticals Corp.'s Annual Meeting of Stockholders. The Company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol PHIO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events rather than financial performance.
Material Changes and Voting Results
On June 15, 2021, stockholders voted on two proposals, both of which were approved:
- Proposal 1 (Election of Directors): Seven nominees were elected to serve until the 2022 Annual Meeting. The total shares present (in person or by proxy) were 6,193,958 out of 13,534,389 issued and outstanding shares.
- Proposal 2 (Ratification of Auditors): Stockholders ratified BDO USA, LLP as the independent registered public accounting firm for the year ending December 31, 2021.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to report the outcome of the shareholder vote.
Investor Verification Checklist
- Verify the election of the seven specific director nominees listed in the filing.
- Confirm the ratification of BDO USA, LLP as the independent auditor.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 30, 2021, for detailed biographical information on directors and the rationale for the auditor selection.
- Note that 4,513,064 shares were recorded as broker non-votes for the director election.